Drugs & Targets FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC February 27, 2026Vol.52 No.08
Drugs & Targets FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer February 20, 2026Vol.52 No.07
Drugs & Targets Siemens Healthineers and Mayo Clinic collaborate to improve care for neurodegenerative disease, cancer February 20, 2026Vol.52 No.07
Drugs & Targets PharmaMar, Globant collaborate to accelerate oncology research with AI February 20, 2026Vol.52 No.07
Drugs & Targets FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma February 13, 2026Vol.52 No.06
Drugs & Targets FDA approves companion diagnostic for pembrolizumab for ovarian cancer February 13, 2026Vol.52 No.06
Drugs & Targets FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency February 06, 2026Vol.52 No.05
Drugs & Targets FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM January 30, 2026Vol.52 No.04
